Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PPARD | Q03181 | 1/20 | 0.61 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cl-277082 SCHEMBL29427720 | 1.00 | SOAT1 (1.00) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL10587602 | 0.93 | SOAT1 (0.86) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9257327 | 0.93 | SOAT1 (0.86) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL1764301 | 0.92 | SOAT1 (0.85) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9784440 | 0.89 | SOAT1 (0.81) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9784517 | 0.88 | SOAT1 (0.78) | SOAT1PPARGPPARAPPARD | |
| SCHEMBL9784452 | 0.87 | SOAT1 (0.77) | SOAT1PPARGPPARAPPARD | |
| SCHEMBL9784620 | 0.87 | SOAT1 (0.76) | SOAT1PPARGPPARAPPARD | |
| SCHEMBL3743567 | 0.86 | SOAT1 (0.75) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9577687 | 0.86 | SOAT1 (0.75) | SOAT1PPARGPPARAPPARDSOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-5003106-A | Antiatherosclerotic ureas and thioureas | AMERICAN CYANAMID COMPANY (US) | 1991-03-26 | — | — | US | claimed |
| US-4623662-A | ANTICHOLESTEROL, ANTILIPEMIC | AMERICAN CYANAMID COMPANY (US) | 1986-11-18 | — | — | US | claimed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| CN-109893528-B | Use of koumine for treating lipid metabolism disorder and related diseases or symptoms thereof | 福建医科大学 | 2022-12-06 | — | — | CN | disclosed |
| EP-3838293-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2872181-B1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-0561175-A1 | Pyrimidine derivatives and pharmaceutical compostions containing them | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-5173510-A | Anticholesterol agents | AMERICAN CYANAMID COMPANY (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0507291-A1 | Cyclohexylurea compounds | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| US-5003106-A | Antiatherosclerotic ureas and thioureas | AMERICAN CYANAMID COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| US-4623662-A | ANTICHOLESTEROL, ANTILIPEMIC | AMERICAN CYANAMID COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | SOAT1 1163/4885PPARG 677/4885PPARA 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.